XML 51 R41.htm IDEA: XBRL DOCUMENT v3.26.1
Revenue Recognition - Nature of Goods and Services (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2026
USD ($)
agreement
segment
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Revenue Recognition [Line Items]      
Number of operating segments | segment 1    
Customers average payment term 30 days    
Distributors average payment term 60 days    
Number of distribution and license agreements | agreement 3    
Net revenue $ 17,336 $ 18,914  
Products Purchase Agreement      
Revenue Recognition [Line Items]      
Product purchase agreement, quarterly non-refundable payments to ensure supply commitment     $ 2,000
Revenue recorded   $ 900  
Sun Pharma, Jeil Pharma, and Drogsan Pharma      
Revenue Recognition [Line Items]      
Deferred revenue $ 300    
Fresenius Medical Care North America | Revenue Benchmark | Customer Concentration Risk      
Revenue Recognition [Line Items]      
Customer concentration, percentage 11.00% 10.00%  
Fresenius Medical Care North America | Accounts Receivable | Customer Concentration Risk      
Revenue Recognition [Line Items]      
Customer concentration, percentage 17.00%    
Nipro Medical Corporation | Revenue Benchmark | Customer Concentration Risk      
Revenue Recognition [Line Items]      
Customer concentration, percentage 10.00%    
Nipro Medical Corporation | Accounts Receivable | Customer Concentration Risk      
Revenue Recognition [Line Items]      
Customer concentration, percentage 17.00%    
Da Vita | Revenue Benchmark | Customer Concentration Risk      
Revenue Recognition [Line Items]      
Customer concentration, percentage   27.00%  
Da Vita | Accounts Receivable | Customer Concentration Risk      
Revenue Recognition [Line Items]      
Customer concentration, percentage     14.00%